Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lung cancer detection via CT scan

This article was originally published in The Gray Sheet

Executive Summary

Among 484 asymptomatic individuals at risk for lung cancer who were diagnosed by low-dose CT in a study conducted from 1993 through 2005, the 10-year lung-cancer-specific survival rate was 80%. The study, published Oct. 26 in The New England Journal of Medicine, showed improved survival rates at 10 years in patients with clinical stage I lung cancer (88%), particularly those who underwent surgical resection within one month after diagnosis (92%). Currently in the U.S., 173,000 people are diagnosed with lung cancer each year, and 164,000 (95%) die from the disease, the report observes. Rates of detection and cost-effectiveness are comparable to those associated with mammographic screening for breast cancer, according to the study...

You may also be interested in...

Study Authors Discourage Widespread CT Screening For Lung Cancer

A study questioning the validity of expensive CT scans for patients at high risk for lung cancer contradicts previous research and dampens the momentum of policy aimed to encourage CT lung cancer screening

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts